Ficoll® Paque Plus

Cytiva 17-1440-02, pack of 6 × 100 mL




shelf life

Please be aware this product may be shipped 90 days before the expiration date. For more information on the batch specific expiration date, please contact technical service.


pack of 6 × 100 mL


Cytiva 17-1440-02


Colorless to slightly yellow

pH range

5.5 - 7.5

General description

Ficoll-Paque Plus is a recognized standard in laboratories worldwide for the isolation of human lymphocytes for in vitro studies.

Ficoll-Paque PLUS is a ready to use, sterile medium for isolation of lymphocytes in high yield from peripheral blood using a simple and rapid centrifugation procedure. It maintains the viability and a representative distribution of B and T lymphocytes.


For in vitro isolation of lymphocytes from human peripheral blood.

Features and Benefits

  • Ready to use sterile medium for isolation of human lymphocytes in high yield from peripheral blood.
  • Maintains viability and representative distribution of B and T lymphocytes.
  • Low levels of endotoxin (< 0.12 EU/mL).

Storage and Stability

Store at 4 to 30 °C ()

Analysis Note

To view the Certificate of Analysis for this product, please visit

Legal Information

Ficoll is a registered trademark of Cytiva


NONH for all modes of transport

Certificate of Analysis

Certificate of Origin

Amalesh Nanda et al.
Annals of laboratory medicine, 40(5), 390-397 (2020-04-21)
The effect of the interplay among inflammation, angiogenesis, extracellular matrix (ECM) degradation, and oxidative stress (OS) on the pathogenesis of endometriosis remains unclear. Previously, we demonstrated the role of OS in endometriosis. Here, we performed a comprehensive investigation of several...
Stanislav Pantelyushin et al.
Cancers, 13(4) (2021-03-07)
Rodent cancer models have limitations in predicting efficacy, tolerability and accompanying biomarkers of ICIs in humans. Companion dogs suffering from neoplastic diseases have gained attention as a highly relevant translational disease model. Despite successful reports of PD-1/PD-L1 blockade in dogs...
Mehdi Hassanpour et al.
Stem cell research & therapy, 11(1), 139-139 (2020-03-29)
To date, many attempts are employed to increase the regenerative potential of stem cells. In this study, we evaluated the hypothesis of whether an autophagy modulation could alter differentiation potency of CD146+ cells into mature pericyte, endothelial, and cardiomyocyte lineage....
Matthew A Lakins et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 26(15), 4154-4167 (2020-04-30)
With the increased prevalence in checkpoint therapy resistance, there remains a significant unmet need for additional therapies for patients with relapsing or refractory cancer. We have developed FS222, a bispecific tetravalent antibody targeting CD137 and PD-L1, to induce T-cell activation...
Jingyong Li et al.
Arteriosclerosis, thrombosis, and vascular biology, 39(3), 446-458 (2019-01-18)
Objective- Inflammation occurs during the progression of abdominal aortic aneurysm (AAA). IL (interleukin)-33 is a pleiotropic cytokine with multiple immunomodulatory effects, yet its role in AAA remains unknown. Approach and Results- Immunoblot, immunohistochemistry, and immunofluorescent staining revealed increased IL-33 expression...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.